S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CDXC ChromaDex Corporation

6.88

-0.32 (-4.44%)

16 Nov 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/23/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Global Shares Financial Services, Filing Agent

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more ChromaDex Charts.

ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more ChromaDex Charts.

ChromaDex Corporation News

ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
Friday 15 November 2024 (2 days ago) • Business Wire

Form 3 - Initial statement of beneficial ownership of securities
Saturday 9 November 2024 (1 week ago) • Edgar (US Regulatory)

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
Friday 8 November 2024 (1 week ago) • Business Wire

ChromaDex Corporation Reports Third Quarter 2024 Financial Results
Friday 1 November 2024 (2 weeks ago) • Business Wire

Form 8-K - Current report
Friday 1 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 1 November 2024 (2 weeks ago) • Edgar (US Regulatory)

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Monday 28 October 2024 (3 weeks ago) • Business Wire

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Thursday 24 October 2024 (3 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 24 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Thursday 24 October 2024 (3 weeks ago) • Edgar (US Regulatory)

ChromaDex to Participate in the 17th Annual LD Micro Main Event
Wednesday 23 October 2024 (3 weeks ago) • Business Wire

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
Tuesday 15 October 2024 (1 month ago) • Business Wire

More ChromaDex Corporation News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions